Balaglitazone

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (±)-5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | image = Balaglitazone.svg | width = 200 | CAS_number = 199113-98-9 | ATC_prefix = none | PubChem = 9572840 | ChemSpiderID = 7846480 | UNII = 0F3X4Q3XUS | KEGG = D03255 | ChEMBL = 2103870 | C=19 | H=25 | N=1 | O=3 | S=1 | smiles = CC1(C)CCCCC1COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 | StdInChI = 1S/C19H25NO3S/c1-19(2)9-4-3-5-10-19-11-23-16-8-6-15(7-12-16)13-14-17(21)20-18(22)24-14/h6-8,12,14H,3-5,9-11,13H2,1-2H3,(H,20,21,22) | StdInChIKey = ZQXKQXUSKJQZKJ-UHFFFAOYSA-N }}

Balaglitazone is a thiazolidinedione (TZD) class drug that was developed for the treatment of type 2 diabetes mellitus. It acts as a peroxisome proliferator-activated receptor gamma (PPARγ) partial agonist. Balaglitazone was designed to improve insulin sensitivity and lower blood glucose levels in patients with type 2 diabetes.

Mechanism of Action

Balaglitazone functions by binding to the PPARγ receptor, which is a type of nuclear receptor that regulates the expression of genes involved in glucose and lipid metabolism. By activating PPARγ, balaglitazone enhances the transcription of insulin-responsive genes, leading to improved insulin sensitivity in peripheral tissues such as muscle and adipose tissue. This results in better control of blood glucose levels.

Unlike full agonists of PPARγ, such as rosiglitazone and pioglitazone, balaglitazone is a partial agonist. This means it activates the receptor to a lesser extent, which may reduce the risk of side effects associated with full activation, such as weight gain and fluid retention.

Clinical Development

Balaglitazone was developed by Dr. Reddy's Laboratories in collaboration with Rheoscience. It underwent several clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. In phase II clinical trials, balaglitazone demonstrated a significant reduction in HbA1c levels, a marker of long-term blood glucose control, compared to placebo.

However, despite promising results, balaglitazone has not been approved for clinical use. The development of the drug was halted, and it has not been marketed in any country.

Side Effects

As a partial agonist of PPARγ, balaglitazone was expected to have a more favorable side effect profile compared to full agonists. Common side effects observed in clinical trials included mild to moderate weight gain and edema. The risk of heart failure, a concern with other TZDs, was thought to be lower with balaglitazone, but further studies would have been needed to confirm this.

Also see

• Thiazolidinedione
• Type 2 diabetes mellitus
• Peroxisome proliferator-activated receptor
• Rosiglitazone
• Pioglitazone